The Clinical Efficacy Of Xianlinggubao Capsule Plus Aclasta For Senile Osteoporosis

Objective:To evaluate the clinical efficacy of Xianlinggubao capsule plus Aclasta for Senile Osteoporosis.Methods:Under the review study method, Choosed 80 cases corresponded to diagnosis and divided into two groups (Research group and Control group):the research group(n=40) were treated by xianlinggubao Capsule plus Aclasta injection, while the control group(n=40) were treated only by Aclasta injection. All the patients received the calcium(Caltrate D, D-Cal and so on) orally inequal quantity. After the treatment for 1、3、6、9、12、24、36 months, the nature and degree of ostealgia in all the patients wereassessed, and the related outcomeindexes were measured.Results:There were no significant differences between the research group and the control group in total significant rates(90.00% for research group vs.82.05% for control group, P<0.05), There were no significant differencesin the degree of pain remission after the treatment(P>0.05), However, Both research group and control groupwere decreased significantlyin the degreesof ostealgiaafter treating(P<0.05). Compared with the control group, the bone density were increased significantly in the research group after treating(P<0.05), Compared with the incidence of osteoporotic fracture,There were no significant diffrence.Conclusions:The treatment of Senile Osteoporosis with Xianlinggubao capsule plus Aclasta has been proved to be effective. In that therapeutic method, the mineral bone density can be increased effectively and the osteoporotic pain inlumbar and back of the patients can be relieved obviously.